Page last updated: 2024-08-21

indazoles and sirolimus

indazoles has been researched along with sirolimus in 89 studies

Research

Studies (89)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (8.99)	29.6817
2010's	77 (86.52)	24.3611
2020's	4 (4.49)	2.80

Authors

Authors	Studies
Kanetake, H; Koga, S	1
Eto, M; Naito, S	1
Mancuso, A; Sternberg, CN	1
Bukowski, RM; Vakkalanka, BK	1
Geng, MY; Li, J; Wang, JJ	1
Albert, DH; Chen, CS; Davidsen, SK; Glaser, KB; Jasinghe, VJ; Khng, J; Poon, LF; Senthilnathan, P; Xie, Z; Zhou, J	1
Bastien, L; Culine, S; de la Taille, A; Ledbai, S; Patard, JJ; Paule, B	1
Cella, D	1
Hudder, A; Novak, RF; Zheng, J; Zukowski, K	1
Bourredjem, A; Daudigeos-Dubus, E; Farace, F; Geoerger, B; Monnet, Y; Opolon, P; Rössler, J; Vassal, G	1
Figlin, RA; Pal, SK	1
Biglietto, M; Buonerba, C; Cartenì, G; Chiurazzi, B; Di Lorenzo, G; Riccardi, F; Scognamiglio, F	1
Maráz, A	1
Karakiewicz, PI; Maurin, C; Perrotte, P; Sun, M; Thuret, R	1
Bergmann, L; Gschwend, J; Keilholz, U; Miller, K	1
Pal, SK; Vogelzang, NJ	2
Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S	1
Steinman, TI	1
Fujioka, T; Iwasaki, K; Obara, W	1
Halfdanarson, TR; Naraev, BG; Strosberg, JR	1
Issels, RD; Lindner, LH	1
Yao, J; Zheng, J; Zou, X	1
Carmichael, C; Ferrell, B; Hsu, J; Lau, C; Liu, X; Pal, SK; Saikia, J; Sun, V; Wilson, T; Yuh, BE	1
Chmielowski, B; Federman, N; Tap, WD	1
Lin, CC; Pu, YS; Wang, JY	1
Borker, R; Fonseca, E; Hess, G	1
Alasker, A; Bianchi, M; Hanna, N; Hansen, J; Ismail, S; Karakiewicz, PI; Meskawi, M; Perrotte, P; Sun, M; Tian, Z	1
Cortesi, E; Iacovelli, R; Mezi, S; Naso, G; Palazzo, A; Pellegrino, D; Trenta, P	1
Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C	1
Caulfield, TR; Cooper, SJ; Copland, JA; Marlow, LA; Tan, WW; Tun, HW; von Roemeling, CA; Wei, JJ; Wu, K	1
Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T	1
Arrowsmith, ER; Crane, EJ; Franco, LA; Hainsworth, JD; Khatcheressian, J; Rubin, MS	1
Christensen, S; Dutia, MP; Eddings, C; Lara, PN; Semrad, TJ	1
De Tursi, M; Felici, A; Lo Re, G; Milella, M; Ricotta, R; Ruggeri, EM; Sabbatini, R; Santini, D; Santoni, M; Vaccaro, V	1
Soulières, D	1
Bruserud, Ø; Hatfield, KJ; Nepstad, I; Reikvam, H	1
Heng, DY; Molina, AM; Motzer, RJ	1
Broom, RJ; Dranitsaris, G; Schmitz, S	1
Brown, NJ; Reed, MW; Staton, CA; Woll, PJ; Young, RJ	1
Chen, S; Cohen-Sola, KA; Goydos, JS; Jeong, BS; Koo, J; Li, J; Lin, Y; Mehnert, JM; Shin, SS; Wen, Y	1
Bold, RJ; Coates, J; Muilenburg, D; Parsons, C; Virudachalam, S	1
Colecchia, M; De Braud, F; Garanzini, E; Grassi, P; Iacovelli, R; Procopio, G; Testa, I; Torelli, T; Verzoni, E	1
Atkinson, BJ; Flaherty, AL; Jonasch, E; Matrana, MR; Shetty, AV; Tannir, NM	1
Bellmunt, J; Calvo, E; Grünwald, V	1
Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R	1
Ferrari, S; Paioli, A; Palmerini, E	1
Corson, JM; Eilers, G; Fletcher, JA; Kuang, Y; Li, H; Li, X; Liu, L; Meng, F; Ou, WB; Sheng, Q; Shi, S; Yan, Z; Zhou, H; Zhou, S	1
Bellmunt, J; Bracarda, S; Cerbone, L; Choueiri, TK; Fay, AP; Foreshew, A; Hutson, TE; Lampron, ME; Pons, F; Porta, C; Powles, T; Sternberg, CN	1
Schmidinger, M	1
Raj, N; Reidy-Lagunes, D	1
Bhowmik, D; Hackshaw, MD; Hutson, TE; Jonasch, E; Rembert, D; Vogelzang, NJ; Yap, M	1
Matsumoto, K; Onda, T; Yaegashi, N	1
Doan, A; Goh, CP; Gunnersen, J; Howitt, J; Lackovic, J; Low, LH; Putz, U; Silke, J; Tan, SS	1
Bex, A; Blank, CU; Broeks, A; de Gruijl, TD; Gadiot, J; Guislain, A; Haanen, JB; Jordanova, ES; Kaiser, A; Sanders, J; van Boven, H	1
Kato, S	1
Aliper, A; Borisov, N; Buzdin, A; Kholodenko, R; Malakhova, G; Roumiantsev, S; Shepelin, D; Suntsova, M; Vasilov, R; Venkova, L; Zhavoronkov, A	1
Abernethy, AP; George, DJ; Harrison, MR; Hirsch, BR; Mitchell, AP; Walker, MS	1
Grünwald, V; Ivanyi, P	1
Chen, KH; Curtis, J; Dasgupta, A; Ghosh, P; Longo, DL; Munk, RB; Sasaki, CY	1
Cartenì, G; Vitale, MG	1
Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ; Yang, C	1
Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S	1
Allen, E; Hanahan, D; Li, L; Miéville, P; Peng, MW; Saghafinia, S; Warren, CM	1
Baudry, M; Bi, X; Liu, Y; O'Neal, P; Sun, J; Tran, J	1
Grünwald, V; Kalanovic, D; Lin, X; Simantov, R	1
Bedke, J; Gauler, T; Grünwald, V; Hegele, A; Herrmann, E; Hinz, S; Janssen, J; Miller, K; Schmitz, S; Schostak, M; Tesch, H; Zastrow, S	1
Chung, J; Joo, J; Joung, JY; Kim, S; Kim, SH; Lee, KH; Seo, HK	1
Azraq, Y; Eleyan, F; Gill, S; Katz, D; Merimsky, O; Peretz, T	1
Golčić, M; Petković, M	1
Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M	1
Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A	1
Joshi, A; Kannan, RA; Kothari, R; Menon, S; Noronha, V; Patil, VM; Popat, P; Prabhash, K; Ramaswamy, A; Sable, N; Sahu, A	1
Afriansyah, A; Hamid, AR; Mochtar, CA; Umbas, R	1
Albersen, M; Bastin, J; Bechter, O; Beuselinck, B; Clement, P; Decallonne, B; Dumez, H; Lerut, E; Oyen, R; Punie, K; Schöffski, P; Vanderschueren, D; Verbiest, A; Werbrouck, E; Wildiers, H; Woei-A-Jin, FJ; Wolter, P	1
Aravantinos, G; Bamias, A; Dimopoulos, MA; Fountzilas, G; Gavalas, N; Gkerzelis, I; Karavasilis, V; Kostouros, E; Koutras, A; Koutsoukos, K; Samantas, E; Tzannis, K; Zagouri, F	1
Jeon, SY; Lee, NR; Yim, CY	1
Joca, SRL; Pereira, VS; Suavinha, ACDR; Wegener, G	1
Donskov, F; Fristrup, N	1
Antoniou, G; Bertulli, R; Blay, JY; Brahmi, M; Casali, PG; Collini, P; Dei Tos, AP; Dufresne, A; Fucà, G; Fumagalli, E; Gronchi, A; Grosso, F; Hindi, N; Jones, RL; Le Cesne, A; Mir, O; Provenzano, S; Sanfilippo, R; Sbaraglia, M; Stacchiotti, S	1
Chandramohan, A; Corn, PG; Devine, CE; Gonzalez, GMN; Karam, JA; Lim, ZD; Msaouel, P; Pruitt, L; Ross, JA; Tannir, NM; Wang, J; Wang, X; Wood, CG; Zurita, AJ	1
Aspinall, SL; Becker, D; Cunningham, FE; Geraci, MC; Good, CB; Heron, BB; Lee, S; Prasad, V; Zhao, X	1
Feng, C; Li, Y; Shen, Y; Wen, H; Zhu, Z	1
Fan, Q; Li, Q; Liu, F; Ma, J; Zhang, B; Zhao, B	1
Bex, A; Hofmann, F; Hwang, EC; Lam, TB; Ljungberg, B; Marconi, LS; Yuan, Y	1

Reviews

34 review(s) available for indazoles and sirolimus

Article	Year
[Progress in therapeutic strategy for renal cell carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Combined Modality Therapy; Female; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Minimally Invasive Surgical Procedures; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib	2006
Molecular targeting therapy for renal cell carcinoma. International journal of clinical oncology, 2006, Volume: 11, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib	2006
New treatment approaches in metastatic renal cell carcinoma. Current opinion in urology, 2006, Volume: 16, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2006
Novel drugs for renal cell carcinoma. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2008
[Recent progress in the study on antitumor drugs targeting hypoxia-inducible factor-1]. Yao xue xue bao = Acta pharmaceutica Sinica, 2008, Volume: 43, Issue:6 Topics: Amphotericin B; Animals; Antineoplastic Agents; Echinomycin; Humans; Hypoxia-Inducible Factor 1; Indazoles; Sirolimus; Topotecan; Transcription, Genetic	2008
Targeted therapies in metastatic renal cancer in 2009. BJU international, 2009, Volume: 103, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factors	2009
Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer treatment reviews, 2009, Volume: 35, Issue:8 Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Health Status; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Patient Satisfaction; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome	2009
The therapy of kidney cancer with biomolecular drugs. Cancer treatment reviews, 2010, Volume: 36 Suppl 3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Immunotherapy; Indazoles; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides; TOR Serine-Threonine Kinases	2010
[Novelties in the treatment for advanced renal-cell cancer]. Orvosi hetilap, 2011, Apr-24, Volume: 152, Issue:17 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2011
[Treatment of metastatic renal cell carcinoma]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2011, Volume: 21, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2011
Targeted therapies for renal cell carcinoma: review of adverse event management strategies. Journal of the National Cancer Institute, 2012, Jan-18, Volume: 104, Issue:2 Topics: Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular System; Drug Eruptions; Europe; Everolimus; Evidence-Based Medicine; Gastrointestinal Tract; Humans; Hypothyroidism; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pneumonia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Weight Loss; Wound Healing	2012
Polycystic kidney disease: a 2011 update. Current opinion in nephrology and hypertension, 2012, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Benzazepines; Curcumin; Everolimus; Gastrointestinal Agents; Glomerular Filtration Rate; Humans; Hypertension; Hypoglycemic Agents; Immunosuppressive Agents; Indazoles; Kidney; Metformin; Octreotide; Organ Size; Polycystic Kidney, Autosomal Dominant; Sirolimus; Sodium; Tolvaptan	2012
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology, 2012, Volume: 83, Issue:3 Topics: Antineoplastic Agents; Benzenesulfonates; Cell Differentiation; ErbB Receptors; Everolimus; Histone Deacetylases; Humans; Immunologic Factors; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Somatostatin; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012
[Soft-tissue sarcoma: recent developments]. Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:31-32 Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Gemcitabine; Humans; Hyperthermia, Induced; Indazoles; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sirolimus; Soft Tissue Neoplasms; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome	2012
Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas. Expert review of anticancer therapy, 2012, Volume: 12, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Drug Substitution; Drugs, Investigational; Endpoint Determination; Humans; Indazoles; Molecular Targeted Therapy; Neoplasm Metastasis; Outcome and Process Assessment, Health Care; Prognosis; Pyrimidines; Sarcoma; Sirolimus; Sulfonamides; Survival Rate; TOR Serine-Threonine Kinases; Treatment Outcome	2012
Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment. American journal of clinical oncology, 2014, Volume: 37, Issue:6 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2	2014
Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. Expert review of anticancer therapy, 2013, Volume: 13, Issue:6 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Palliative Care; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases	2013
Side-effects associated with targeted therapies in renal cell carcinoma. Current opinion in supportive and palliative care, 2013, Volume: 7, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; Sunitinib	2013
Systemic treatment options for untreated patients with metastatic clear cell renal cancer. Seminars in oncology, 2013, Volume: 40, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib	2013
Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy. Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:11 Topics: Antineoplastic Agents; Axitinib; Bayes Theorem; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides	2013
Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:7 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quality of Life; Sirolimus; Vascular Endothelial Growth Factor A	2014
Emerging therapeutic targets for synovial sarcoma. Expert review of anticancer therapy, 2014, Volume: 14, Issue:7 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sarcoma, Synovial; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases	2014
Improving outcomes in metastatic clear cell renal cell carcinoma by sequencing therapy. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2014 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Patient Selection; Sirolimus; Treatment Outcome	2014
Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors. Pancreas, 2014, Volume: 43, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Differentiation; Chemoradiotherapy; Clinical Trials as Topic; Drugs, Investigational; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neuroendocrine Tumors; Octreotide; Peptides, Cyclic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radioisotopes; Sirolimus; Somatostatin; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2014
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives. Japanese journal of clinical oncology, 2015, Volume: 45, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids	2015
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2015
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?]. Aktuelle Urologie, 2015, Volume: 46, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Immunotherapy; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis	2015
Clinical management of metastatic kidney cancer: the role of new molecular drugs. Future oncology (London, England), 2016, Volume: 12, Issue:1 Topics: Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2016
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials. Anti-cancer drugs, 2016, Volume: 27, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2016
Systemic therapy in metastatic renal cell carcinoma. World journal of urology, 2017, Volume: 35, Issue:2 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Decision Trees; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Nivolumab; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2017
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer treatment reviews, 2016, Volume: 50 Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA-Binding Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; MicroRNAs; Molecular Targeted Therapy; Mutation; Niacinamide; Nivolumab; Nuclear Proteins; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Pyrimidines; Pyrroles; Quinolines; Receptors, CCR4; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein	2016
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. European urology, 2017, Volume: 71, Issue:3 Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2017
Targeted Therapy for Metastatic Renal Cell Carcinoma. Acta medica Indonesiana, 2016, Volume: 48, Issue:4 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2016
Targeted therapy for metastatic renal cell carcinoma. The Cochrane database of systematic reviews, 2020, 10-14, Volume: 10 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Axitinib; Bevacizumab; Bias; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Phenylurea Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2020

Trials

7 trial(s) available for indazoles and sirolimus

Article	Year
Quality of life in patients with metastatic renal cell carcinoma: assessment of long-term survivors. Clinical genitourinary cancer, 2013, Volume: 11, Issue:2 Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Everolimus; Female; Humans; Immunosuppressive Agents; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pilot Projects; Pyrimidines; Quality of Life; Sirolimus; Sulfonamides; Surveys and Questionnaires; Survivors; Treatment Outcome	2013
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. British journal of cancer, 2013, Apr-30, Volume: 108, Issue:8 Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate	2013
Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. Clinical genitourinary cancer, 2013, Volume: 11, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; Sunitinib; Treatment Outcome	2013
Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anti-cancer drugs, 2013, Volume: 24, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases	2013
Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India. Clinical genitourinary cancer, 2017, Volume: 15, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Tertiary Care Centers; Treatment Outcome; Young Adult	2017
The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. International journal of clinical oncology, 2019, Volume: 24, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2019
Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. European urology oncology, 2020, Volume: 3, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Risk Assessment; Single-Blind Method; Sirolimus; Sulfonamides	2020

Other Studies

48 other study(ies) available for indazoles and sirolimus

Article	Year
ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. Journal of hepatology, 2008, Volume: 49, Issue:6 Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Survival; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Indazoles; Liver Neoplasms; Mice; Mice, SCID; Neovascularization, Pathologic; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinases; Receptor Protein-Tyrosine Kinases; Sirolimus; Subcutaneous Fat; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2008
StatBite: FDA oncology drug product approvals in 2009. Journal of the National Cancer Institute, 2010, Feb-24, Volume: 102, Issue:4 Topics: Administration, Oral; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cetuximab; Depsipeptides; Drug Approval; Everolimus; Ferrosoferric Oxide; Glutamates; Guanine; Humans; Indazoles; Injections; Panitumumab; Pemetrexed; Pyrimidines; Sirolimus; Sulfonamides; United States; United States Food and Drug Administration	2010
Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells. Cancer letters, 2010, Oct-01, Volume: 296, Issue:1 Topics: Breast Neoplasms; Cell Cycle; Cell Division; Cell Line, Tumor; Enzyme Activation; Epithelial Cells; Female; Fibrocystic Breast Disease; Flow Cytometry; Humans; Immunoblotting; Indazoles; Indoles; Neoplasm Metastasis; Proto-Oncogene Proteins c-akt; Sirolimus; Survivors	2010
Everolimus and pazopanib: two new drugs for renal cell cancer. The Medical letter on drugs and therapeutics, 2010, May-03, Volume: 52, Issue:1337 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Interactions; Everolimus; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sirolimus; Sulfonamides	2010
The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts. International journal of cancer, 2011, Jun-01, Volume: 128, Issue:11 Topics: Animals; Apoptosis; Axitinib; Blotting, Western; Bone Marrow Neoplasms; Child; Drug Synergism; Endothelium, Vascular; Humans; Imidazoles; Indazoles; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Neuroblastoma; Phosphorylation; Sirolimus; Stem Cells; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays	2011
Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules. Expert opinion on biological therapy, 2010, Volume: 10, Issue:11 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis	2010
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Aktuelle Urologie, 2011, Volume: 42, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cooperative Behavior; Cytokines; Disease Progression; Everolimus; Evidence-Based Medicine; Humans; Indazoles; Indoles; Interdisciplinary Communication; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Care Team; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2011
Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS. Clinical genitourinary cancer, 2011, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Management; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Sirolimus; Treatment Failure	2011
Case of complete response to everolimus for metastatic renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:9 Topics: Abdominal Cavity; Acute Kidney Injury; Axitinib; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Imidazoles; Immunosuppressive Agents; Indazoles; Interferon-alpha; Kidney Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nephrectomy; Protein Kinase Inhibitors; Remission Induction; Sirolimus; Tomography, X-Ray Computed; Withholding Treatment	2012
The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells. Chemotherapy, 2012, Volume: 58, Issue:4 Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Down-Regulation; Female; Humans; Indazoles; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases	2012
Active tuberculosis during temsirolimus and bevacizumab treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-10, Volume: 31, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic; Sirolimus; Tuberculosis	2013
Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting. Clinical genitourinary cancer, 2013, Volume: 11, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; United States	2013
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position. Clinical genitourinary cancer, 2013, Volume: 11, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome	2013
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma. Cancer treatment reviews, 2013, Volume: 39, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2013
Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-01, Volume: 19, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Synergism; Female; Gene Expression; Humans; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Pyrimidines; Pyrroles; Sirolimus; Stearoyl-CoA Desaturase; Sulfonamides; Sunitinib; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays	2013
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2013, Volume: 71, Issue:9 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid	2013
Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells. Oncotarget, 2013, Volume: 4, Issue:6 Topics: Adenine; Adult; Aged; Aged, 80 and over; Bone Marrow Cells; Cytogenetics; Cytokines; Female; Humans; Indazoles; Leukemia, Myeloid, Acute; Male; Middle Aged; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; RNA, Messenger; Signal Transduction; Sirolimus; Stromal Cells; Sulfonamides; TOR Serine-Threonine Kinases; Young Adult	2013
Vascular-targeted agents for the treatment of angiosarcoma. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Axitinib; Bevacizumab; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Movement; Doxorubicin; Everolimus; Hemangiosarcoma; Humans; Imidazoles; Indazoles; Neovascularization, Pathologic; Paclitaxel; Protein Array Analysis; Sirolimus; Vascular Endothelial Growth Factor A	2014
Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression. Cancer research, 2014, May-01, Volume: 74, Issue:9 Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Heterocyclic Compounds, 3-Ring; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Inhibitor of Apoptosis Proteins; Interleukin-8; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Receptors, Metabotropic Glutamate; Riluzole; Signal Transduction; Sirolimus; Skin Neoplasms; Survivin; Tumor Burden; Vascular Endothelial Growth Factor A	2014
Role of autophagy in apoptotic regulation by Akt in pancreatic cancer. Anticancer research, 2014, Volume: 34, Issue:2 Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Autophagy; Caspases; Cell Line, Tumor; Enzyme Activation; Humans; Indazoles; Indoles; Microscopy, Fluorescence; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases	2014
Treatment of collecting duct carcinoma: current status and future perspectives. Anticancer research, 2014, Volume: 34, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides	2014
Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience. Clinical genitourinary cancer, 2014, Volume: 12, Issue:5 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Treatment Outcome	2014
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. European urology, 2014, Volume: 66, Issue:3 Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid	2014
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma. British journal of cancer, 2014, May-13, Volume: 110, Issue:10 Topics: Antineoplastic Agents; Butadienes; Cell Cycle; Cell Line, Tumor; Chromones; Drug Screening Assays, Antitumor; Enzyme Activation; Everolimus; Humans; Imidazoles; Indazoles; MAP Kinase Signaling System; Mesothelioma; Molecular Targeted Therapy; Morpholines; Neoplasm Proteins; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinolines; raf Kinases; Receptor Protein-Tyrosine Kinases; RNA Interference; RNA, Small Interfering; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases	2014
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. Clinical genitourinary cancer, 2014, Volume: 12, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2014
News products to avoid. Prescrire international, 2014, Volume: 23, Issue:148 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Azacitidine; Decitabine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Everolimus; Ferrosoferric Oxide; Gefitinib; Hematinics; Humans; Imidazoles; Indazoles; Oxonic Acid; Pyridines; Quinazolines; Risk Assessment; Risk Factors; Sirolimus; Tegafur	2014
First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting. Clinical genitourinary cancer, 2015, Volume: 13, Issue:3 Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Community Networks; Electronic Health Records; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sirolimus; Sulfonamides; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; United States; Young Adult	2015
Ndfip1 represses cell proliferation by controlling Pten localization and signaling specificity. Journal of molecular cell biology, 2015, Volume: 7, Issue:2 Topics: Active Transport, Cell Nucleus; Animals; Carrier Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Female; Indazoles; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Microcephaly; PC12 Cells; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; PTEN Phosphohydrolase; Rats; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases	2015
Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer immunology, immunotherapy : CII, 2015, Volume: 64, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Everolimus; Female; Humans; Immunotherapy; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Cells; Neoplasm Metastasis; Programmed Cell Death 1 Receptor; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib; T-Lymphocytes; Treatment Outcome	2015
Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs. Oncotarget, 2015, Sep-29, Volume: 6, Issue:29 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; HeLa Cells; Hep G2 Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Jurkat Cells; MCF-7 Cells; Neoplasms; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcriptome	2015
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. Journal of oncology practice, 2015, Volume: 11, Issue:6 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Patients; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2015
Mechanism of Activation-Induced Downregulation of Mitofusin 2 in Human Peripheral Blood T Cells. Journal of immunology (Baltimore, Md. : 1950), 2015, Dec-15, Volume: 195, Issue:12 Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Down-Regulation; GTP Phosphohydrolases; Humans; Indazoles; Indoles; Leukocytes, Mononuclear; Lymphocyte Activation; Mitochondrial Proteins; Morpholines; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Sirolimus; T-Lymphocytes; TOR Serine-Threonine Kinases	2015
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. Current medical research and opinion, 2016, Volume: 32, Issue:4 Topics: Aged; Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; United States	2016
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC). Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Singapore; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2015
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell reports, 2016, 05-10, Volume: 15, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glucose; Glutamine; Glycolysis; Humans; Imidazoles; Indazoles; Indoles; Intestinal Neoplasms; Lactic Acid; Membrane Transport Proteins; Mice; Models, Biological; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sirolimus; Stomach Neoplasms; Sunitinib; TOR Serine-Threonine Kinases; Up-Regulation	2016
mTORC1-S6K1 inhibition or mTORC2 activation improves hippocampal synaptic plasticity and learning in Angelman syndrome mice. Cellular and molecular life sciences : CMLS, 2016, Volume: 73, Issue:22 Topics: Actins; Angelman Syndrome; Animals; Blood Proteins; Cytoskeletal Proteins; Hippocampus; Imidazoles; Indazoles; Indoles; Learning; Long-Term Potentiation; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Nerve Tissue Proteins; Neuronal Plasticity; Piperazines; Polymerization; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2016
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. European urology, 2016, Volume: 70, Issue:6 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden	2016
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy. BMC cancer, 2016, 08-02, Volume: 16 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome	2016
Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis. BMC cancer, 2016, 08-08, Volume: 16 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chondrosarcoma; Disease Progression; Drug Administration Schedule; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sarcoma; Sirolimus; Sulfonamides; Survival Analysis; Treatment Outcome; Young Adult	2016
Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer - A new potential biomarker? Medical hypotheses, 2016, Volume: 94 Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cholesterol; Ferritins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypothyroidism; Indazoles; Indoles; Iron; Kidney Neoplasms; Lipids; Metabolome; Models, Theoretical; Neoplasm Metastasis; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Triglycerides	2016
Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies. Acta clinica Belgica, 2019, Volume: 74, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cross-Sectional Studies; Humans; Hypogonadism; Indazoles; Kidney Neoplasms; Luteinizing Hormone; Male; Middle Aged; Molecular Targeted Therapy; Prevalence; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib; Testosterone; Vascular Endothelial Growth Factor A	2019
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report. BMC nephrology, 2019, 01-03, Volume: 20, Issue:1 Topics: Aged; Amlodipine; Angiogenesis Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Diabetic Nephropathies; Dihydropyridines; Drug Substitution; Edema; Everolimus; Humans; Hypertension; Indazoles; Kidney Failure, Chronic; Lung Neoplasms; Male; Nephrotic Syndrome; Nivolumab; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pneumonectomy; Protein Kinase Inhibitors; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib	2019
Prelimbic neuronal nitric oxide synthase inhibition exerts antidepressant-like effects independently of BDNF signalling cascades. Acta neuropsychiatrica, 2019, Volume: 31, Issue:3 Topics: Animals; Antidepressive Agents; Apomorphine; Brain-Derived Neurotrophic Factor; Carbazoles; Immobility Response, Tonic; Indazoles; Indole Alkaloids; Isoquinolines; Ketamine; Locomotion; Male; Microinjections; Nitric Oxide Synthase Type I; Ornithine; Prefrontal Cortex; Rats; Receptor, trkB; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2019
Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study. Clinical genitourinary cancer, 2019, Volume: 17, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Female; Folic Acid; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sirolimus; Sulfonamides; Sunitinib; Treatment Outcome	2019
Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 09-01, Volume: 25, Issue:17 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Everolimus; Female; Gemcitabine; Humans; Indazoles; International Agencies; Male; Middle Aged; Perivascular Epithelioid Cell Neoplasms; Prognosis; Pyrimidines; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-1	2019
Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration. Cancer medicine, 2019, Volume: 8, Issue:15 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Pyrimidines; Retrospective Studies; Sirolimus; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; United States; United States Department of Veterans Affairs	2019
Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation. Cancer medicine, 2020, Volume: 9, Issue:16 Topics: Anilides; Antineoplastic Agents; Arylsulfotransferase; Axitinib; Carcinoma, Renal Cell; Carrier Proteins; Cell Line, Tumor; Chromogranins; Computer Simulation; Cyclin E; DNA Copy Number Variations; Drug Resistance, Neoplasm; GTP-Binding Protein alpha Subunits, Gs; Humans; Indazoles; Kidney Neoplasms; Oncogene Proteins; Pituitary Adenylate Cyclase-Activating Polypeptide; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib	2020
Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system. Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:5 Topics: Acute Kidney Injury; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Azetidines; Benzamides; Female; Hospital Mortality; Hospitalization; Humans; Indazoles; Male; Middle Aged; Odds Ratio; Pharmacovigilance; Piperidines; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Sirolimus; United States; United States Food and Drug Administration; Young Adult	2020